Obiettivo Dwarfbody-Therapeutics (DB-Tx) is a new company, established in 2016 as a spin off from a frontrunner research team in Gastro-Intestinal Cancers in the AMC Amsterdam. DB-Tx aims to transform current, ineffective treatment of these aggressive cancer types by co-administering highly effective and safe low molecular weight antibodies (“Dwarfbodies®”) to significantly increase therapeutic outcome. The superiority of the Dwarfbodies® compared to competing molecules and their anticancer effects have been published in various high ranked journals. Now PANTREAT primarily aims at broadening the initial target market for the Dwarfbodies® by creating additional proof-of-concept, reports on production, test Trial Centers and a sound business plan. Results will be compiled into a sound company portfolio, which will form the basis for further development of the Dwarfbodies® and obtaining investments and supportive grants and partnerships. Finally, this will lead to highly attractive licencing deals from 2020 onwards. Campo scientifico medical and health sciencesclinical medicineoncologypancreatic cancermedical and health sciencesbasic medicinetoxicology Programma(i) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Argomento(i) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Invito a presentare proposte H2020-SMEInst-2016-2017 Vedi altri progetti per questo bando Bando secondario H2020-SMEINST-1-2016-2017 Meccanismo di finanziamento SME-1 - SME instrument phase 1 Coordinatore DWARFBODY-THERAPEUTICS WERKMAATSCHAPPIJ BV Contribution nette de l'UE € 50 000,00 Indirizzo KWEEKDUINWEG 12 2051 EL OVERVEEN Paesi Bassi Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione West-Nederland Noord-Holland Agglomeratie Haarlem Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 71 429,00
